课题基金 / 基金详情

Targeted therapy in ex vivo medulloblastoma/PNET

Targeted therapy in ex vivo medulloblastoma/PNET
离体髓母细胞瘤/PNET 靶向治疗
批准号:
8460818
负责人:
JAMES M OLSON
金额:
$21.37万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-06 至 2017-03-31

项目摘要

项目成果

JAMES M OLSON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):髓母细胞瘤和原始神经外胚层(PNET)脑瘤的儿童被分为中等风险组和高风险组,以便根据需要调整治疗强度。不幸的是,对患者进行分层的方法并不完善,因此被归类为“中等风险”的儿童中有25%未能通过治疗而死于疾病。我们已经确定P27缺失是识别大多数这些儿童的生物标志物,可以用来适当地将他们归入高危类别,在这种类别中,他们将接受强化治疗,以增加生存机会。另一个临床问题是,PNET患者在临床试验中与髓母细胞瘤患者分组,并进行相同的治疗。我们最近了解到,PNET肿瘤在分子上与髓母细胞瘤不同,PNET患者对为髓母细胞瘤患者量身定做的治疗反应很差。针对这种疾病量身定做sPNET治疗的关键障碍是缺乏相关的sPNET临床前模型。我们已经产生了患者来源的sPNET干细胞培养和原位小鼠模型,并使用它们来识别FDA批准的药物,这些药物在临床前研究中比目前使用的药物更有效。在这次更新应用中,我们的具体目标是:1)确定髓母细胞瘤和sPNET患者治疗失败的预后指标。2)为未来的临床试验确定靶向治疗的优先顺序。预期结果是:1)我们将在对300名患者的前瞻性分析中进一步提炼适合患者分层的分子生物标记物;2)我们将产生临床相关的sPNET和高风险髓母细胞瘤临床前模型;3)与我们的记录一致,我们将推广一种用于人类sPNET和高风险髓母细胞瘤试验的方案,该方案基于超过所有现有标准的研究,将临床前研究成果推进到临床试验。这个 重要的是,我们最终将放弃陈旧的患者分层方案,转而采用基于生物学的策略,适当地引导患者进行量身定制的治疗,并根据相关的临床前和临床数据对sPNET患者进行治疗。最终,这两种药物都将产生更高的治愈率,并限制对儿童麸皮肿瘤患者的毒性。
英文摘要
DESCRIPTION (provided by applicant): Children with medulloblastoma and primitive neuroectodermal (PNET) brain tumors are divided into average- and high-risk groups so that therapy intensity can be tailored. Unfortunately, the methods for stratifying patients are imperfect, so that > 25% of children categorized as "average risk" fail therapy and die of disease. We have identified P27 loss as a biomarker that identifies most of these children and could be used to appropriately place them in the high-risk category, where they would receive intensified therapy increasing survival chances. Another clinical problem is that PNET patients are grouped with medulloblastoma patients in clinical trials and treated identically. We have recently learned that PNET tumors are molecularly distinct from medulloblastomas and that PNET patients respond poorly to therapy that has been tailored for medulloblastoma patients. The critical barrier to tailoring sPNET therapy to the disease has been the lack of relevant sPNET pre-clinical models. We have generated patient-derived sPNET stem cell cultures and orthotopic mouse models and have used these to identify FDA-approved drugs that are more efficacious in pre-clinical studies than currently used drugs. In this renewal application, our Specific Aims are: 1) To identify prognostic indicators of therapy failure for medulloblastoma and sPNET patients. 2) To prioritize targeted therapies for future clinical trials. The expected outcomes are: 1) that we will further refine molecular biomarkers suitable for patient stratificatin in a prospective analysis of > 300 patients; 2) that we will generate clinically relevant sPNET and high risk medulloblastoma pre-clinical models and 3) consistent with our track record, we will promote a regimen for human sPNET and high risk medulloblastoma trials based on studies that exceed all current standards for advancement of pre-clinical results into clinical trials. The significance is that we will ultimately abandon an archaic patient stratification scheme in favor o a biologically-based strategy that appropriately directs patients into tailored therapy and that sPNET patients will be treated with therapeutic regimens that are based on relevant pre-clinical and clinical data. Ultimately both will yield higher cure rates and limit toxicity in pediatric bran tumor patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted Therapy in Ex Vivo Medulloblastoma
  • 批准号:
    10531422
  • 项目类别:
  • 资助金额:
    $43.87万
  • 财政年份:
    2022
  • 负责人:
    JAMES M OLSON
  • 依托单位:
Engineering Knotted Peptide Therapeutics for Pediatric Brain Tumor Patients
  • 批准号:
    10531428
  • 项目类别:
  • 资助金额:
    $64.47万
  • 财政年份:
    2022
  • 负责人:
    JAMES M OLSON
  • 依托单位:
Targeted Therapy in Ex Vivo Medulloblastoma
  • 批准号:
    10560551
  • 项目类别:
  • 资助金额:
    $43.87万
  • 财政年份:
    2022
  • 负责人:
    JAMES M OLSON
  • 依托单位:
Targeted Therapy in Ex Vivo Medulloblastoma
  • 批准号:
    10738311
  • 项目类别:
  • 资助金额:
    $13.74万
  • 财政年份:
    2022
  • 负责人:
    JAMES M OLSON
  • 依托单位:
海外基金